Psoriatic arthritis
Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the 2025 ACR Convergence meeting in Chicago.
Dr. John Cush RheumNow
4 days 9 hours ago
Psoriatic Arthritis Imaging
Dr. Arthur Kavanaugh talks about imaging in psoriatic arthritis at #ACR25
https://t.co/l6MKTgEJXu https://t.co/sKhoQWCPli
Nouf Al hemmadi NoufAhmedAlham2
4 days 15 hours ago
GLP-1 Receptor Agonists in PsA: Mortality and MACE https://t.co/GtTGHY7j5g
@synovialjoints discussed TriNetX data base looking at GLP-1 medications effect on MACE in PsA patients.
@RheumNow
#ACR25
Janet Pope Janetbirdope
4 days 19 hours ago
What happens if you have #axSpA & concomitant #FM?
Pts with both have less TNFi retention,
-residual pain may lead to d/c Rx.
Need to determine if axSpA pt has #fibromyalgia as there may not be objective findings if no peripheral arthritis in axSpA.
#ACR25 @RheumNow abst#534
A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the interleukin-23 receptor (IL-23R), is showing encouraging efficacy and safety across a range of psoriasis (PSO) and psoriatic disease (PsD) studies.
Antoni Chan MD (Prof) synovialjoints
5 days 14 hours ago
In a PsA cohort (n=1291), higher BMI was independently linked to lower odds of achieving MDA—especially in TNFi-treated patients. Impact was strongest in pain, skin, enthesitis, and PRO domains, not swollen joints. Each unit increase in BMI reduced MDA odds by 4–7%. Highlights https://t.co/TxO3HP51uk
Mrinalini Dey DrMiniDey
5 days 14 hours ago
#2686 Using HR-pQCT, researchers tracked bone changes in RA & PsA. Seropositive RA showed worst bone density & microstructure, worsening with disease activity. TNFi, RTX & BARI improved MCP bone density, highlighting the impact of inflammation and treatment. @RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD
5 days 14 hours ago
GLP-1 RA vs DPP4i & risk of rheumatic disease: propensity score matched cohort study using TriNetX
🔹 Lower incidence of OA, RA & gout w/ GLP-1 RA
🔹 No significant differences for PsA, SSc, axSpA, or SLE
@RheumNow #ACR25 https://t.co/BIVw3ajrFZ
Janet Pope Janetbirdope
5 days 14 hours ago
#Deucravacitinib #Tyk2i in active #PsA to 52weeks
#PBO was crossed over at 16weeks
Ongoing improvement for high bar outcomes ex % in #minimal #disease #activity #MDA
#Xray #progression was reduced with real data (not imputed)
#ACR2025 @RheumNow @ACRheum https://t.co/kAMym2x8HQ
Akhil Sood MD, MS AkhilSoodMD
5 days 14 hours ago
Abstract 2687: GLP-1 RA in PsA
In combined Toronto + NYU cohort, GLP-1 RA significantly associated with reduced:
- Weight, CRP, and pain scores
- Each 1% reduction in body weight associated w/ TJC, DAPSA, EQ-5D (QoL), LDL, Systolic BP
@RheumNow #ACR25 https://t.co/30lPDkALKs
Poster Hall